• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket

    2/28/23 7:57:23 AM ET
    $ADMP
    $AHCO
    $APTX
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • Catalyst Biosciences Inc (NASDAQ:CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has signed an asset purchase agreement with Catalyst Biosciences to acquire 3 programs related to the orphan hematology disorders.
    • Intelligent Living Application Group Inc. (NASDAQ:ILAG) rose 40.3% to $1.74 in pre-market trading after the company announced plans to develop advanced smart home security devices.
    • Obseva SA (NASDAQ:OBSV) shares rose 24.4% to $0.12 in pre-market trading after gaining over 16% on Monday. ObsEva announced strategic reorganization to consolidate operations in Switzerland.
    • Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rose 23.1% to $0.3244 in pre-market trading. Adamis Pharmaceuticals and DMK Pharmaceuticals announced agreement and plan of merger.
    • Mount Rainier Acquisition Corp (NASDAQ:RNER) rose 19.8% to $6.05 in pre-market trading. Mount Rainier Acquisition shares dropped 46% on Monday possibly after the company's general meeting was cancelled on Sunday.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) rose 15.9% to $0.40 in pre-market trading after dropping 10% on Monday.
    • Progyny Inc (NASDAQ:PGNY) shares rose 14.6% to $35.62 in pre-market trading after the company reported better-than-expected Q4 results.
    • AIM ImmunoTech Inc (NYSE:AIM) rose 14.6% to $0.55 in pre-market trading after dropping over 7% on Monday. AIM ImmunoTech, last month, entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.
    • Ocugen Inc (NASDAQ:OCGN) rose 11.7% to $1.09 in pre-market trading. Ocugen announced submission of investigational new drug application with the FDA to initiate Phase 1 clinical trial evaluating OCU200 for the treatment of diabetic macular edema.
    • Smart for Life Inc (NASDAQ:SMFL) shares rose 10.5% to $0.21 in pre-market trading after gaining over 7% on Monday.

    Losers

    • Aptinyx Inc (NASDAQ:APTX) shares fell 63.6% to $0.22 in pre-market trading after the company reported results from Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson's disease and dementia with lewy bodies and issued pipeline and corporate update.
    • Verde Clean Fuels Inc (NASDAQ:VGAS) fell 18.8% to $10.00 in pre-market after dropping around 17% on Monday.
    • Adapthealth Corp (NASDAQ:AHCO) fell 18.3% to $17.95 in pre-market trading after the company posted a loss for the fourth quarter.
    • Lucira Health Inc (NASDAQ:LHDX) fell 14.7% to $0.43 in pre-market trading. Lucira Health shares jumped 264% on Monday after the company announced FDA authorization for its at-home combination COVID-19 & flu test.
    • Sera Prognostics Inc (NASDAQ:SERA) shares dropped 13.9% to $3.40 in pre-market trading after jumping 18% on Monday. The company recently announced top-line data from the AVERT PRETERM TRIAL.
    • NewtekOne Inc (NASDAQ:NEWT) fell 12.8% to $16.80 in pre-market trading following weaker-than-expected Q4 results.
    • COMSovereign Holding Corp (NASDAQ:COMS) fell 7.6% to $3.39 in pre-market trading after gaining around 10% on Monday. COMSovereign recently announced an 80% year-over-year reduction of outstanding secured debt.
    • Performance Shipping Inc (NASDAQ:PSHG) fell 7.4% to $2.50 in pre-market trading. Performance Shipping announced termination of at-the-market offering.
    • Smith Micro Software, Inc. (NASDAQ:SMSI) shares fell 6.9% to $1.48 in pre-market trading. Smith Micro Software shares dropped 36% on Monday after the company announced it received written notice of contract termination from a U.S.-based Tier 1 carrier customer for the company's family safety solution.
    • Milestone Scientific Inc (NYSE:MLSS) fell 6.4% to $0.71 in pre-market trading after surging 18% on Monday. Milestone Scientific announced 510(k) FDA clearance for the use of CompuFlo® Epidural System in thoracic indications.

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Tech Stocks Delivering High-Dividend Yields

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AHCO
    $APTX
    $CBIO

    CompanyDatePrice TargetRatingAnalyst
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Progyny Inc.
    $PGNY
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Progyny Inc.
    $PGNY
    1/8/2026$34.00Hold → Buy
    Truist
    Sera Prognostics Inc.
    $SERA
    12/15/2025$5.00Buy
    Jefferies
    Progyny Inc.
    $PGNY
    12/9/2025$29.00Overweight
    Barclays
    More analyst ratings

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cummings Melissa B

    4 - Progyny, Inc. (0001551306) (Issuer)

    4/16/26 4:16:11 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 4 filed by Hrt Financial Lp

    4 - Lion Group Holding Ltd (0001806524) (Issuer)

    4/13/26 10:17:24 AM ET
    $LGHL
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Hrt Financial Lp

    4 - Lion Group Holding Ltd (0001806524) (Issuer)

    4/9/26 12:04:19 PM ET
    $LGHL
    Investment Bankers/Brokers/Service
    Finance

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cashin Richard M Jr bought $19,912,148 worth of shares (2,046,691 units at $9.73) (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/12/26 9:11:41 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Ocugen with a new price target

    Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00

    3/17/26 8:33:47 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Ocugen with a new price target

    Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00

    3/11/26 8:39:19 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    SEC Filings

    View All

    SEC Form 20-F filed by Intelligent Living Application Group Inc.

    20-F - Intelligent Living Application Group Inc. (0001814963) (Filer)

    4/24/26 4:30:57 PM ET
    $ILAG
    Office Equipment/Supplies/Services
    Consumer Discretionary

    SEC Form DEFA14A filed by Sera Prognostics Inc.

    DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    4/24/26 4:11:50 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Sera Prognostics Inc.

    DEF 14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    4/24/26 4:10:34 PM ET
    $SERA
    Medical Specialities
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 12,525 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on April 23, 2026 and were material to each employee's acceptan

    4/24/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An

    4/23/26 1:55:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Ocugen to Present at April 2026 Investor and Industry Conferences

    MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy. "I look forward to sharing our story with new audiences and building enthusiasm f

    4/23/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An

    4/23/26 1:55:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Smith Micro Schedules Teleconference to Announce First Quarter 2026 Financial Results

    Smith Micro Software, Inc. (NASDAQ:SMSI) announced that it will report its first quarter 2026 financial results following the close of regular trading on Wednesday, April 29, 2026. The news release will be followed by a teleconference available to all interested parties at 4:30 pm ET / 1:30 pm PT. The Smith Micro first quarter conference call may be accessed as follows: Date and Time: Wednesday, April 29, 2026 at 4:30 pm ET / 1:30 pm PT News Release: Available in Smith Micro's Newsroom Teleconference: Dial 1-844-701-1164 ten minutes before the start of the call. International participants can call 1-412-317-5492 A passcode is not required to access the teleconference. Ask the oper

    4/22/26 4:01:00 PM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Verde Clean Fuels, Inc. Announces New CEO and Engagement of Financial Advisor to Evaluate Strategic Alternatives

    George Burdette, current Chief Financial Officer, appointed Chief Executive Officer Roth Capital Partners retained as financial advisor to evaluate strategic alternatives, including potential merger or sale Verde Clean Fuels, Inc. (NASDAQ:VGAS) ("Verde" or the "Company") announced today the appointment of George Burdette as Chief Executive Officer ("CEO") and engagement of Roth Capital Partners ("Roth") as financial advisor to assist the Company in evaluating strategic alternatives. These announcements are part of the Company's continued advancement of its previously announced restructuring and cost reduction initiatives. Mr. Burdette succeeds Ernie Miller who is stepping down from h

    3/20/26 6:13:00 PM ET
    $FSLR
    $VGAS
    Semiconductors
    Technology
    Major Chemicals
    Industrials

    Smith Micro Announces Tim Huffmyer to Succeed Bill Smith as President and CEO

    Smith Micro Software, Inc. (NASDAQ:SMSI) today announced that it has named current Chief Operating Officer and Chief Financial Officer Tim Huffmyer to serve as Smith Micro's next President and Chief Executive Officer. Huffmyer will assume the role from Bill Smith, who has been appointed to the role of Executive Chairman. The changes will take effect on March 31, 2026 and follow leadership succession planning led by Smith and the Company's Board of Directors. "This planned leadership transition reflects the Board's ongoing succession planning and commitment to continuity in leadership and disciplined execution," said Smith. "With Tim's demonstrated strategic, financial and operational perf

    3/4/26 4:03:00 PM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $AHCO
    $APTX
    $CBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Smith Micro Software Inc.

    SC 13G/A - SMITH MICRO SOFTWARE, INC. (0000948708) (Subject)

    11/15/24 8:30:55 AM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology